ArticleChemistry & biodiversity2026
Antifungal Activity of Hedychium spicatum Essential Oil Against Candidemia-Causing Candida tropicalis and Candida parapsilosis: In Vitro Evaluation and Computational Identification of Cis-γ-Bisabolene as a Putative CYP51-Binding Constituent.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candidiasis is caused by Candida parapsilosis and Candida tropicalis emerges due to antifungal resistance and limited therapies. We aim to assess the antifungal activity of Hedychium spicatum essential oil (HSEO), followed by computational analyses to identify potential lead phytochemicals, targeting lanosterol 14α-demethylase (CYP51), a key enzyme in ergosterol biosynthesis. GC-MS identified 29 phytoconstituents, with τ-cadinol (17.94%) as the major component. Disc diffusion demonstrated concentration-dependent antifungal activity against C. parapsilosis and C. tropicalis, with inhibition zones of 11.00 ± 0.53 and 10.40 ± 0.36 mm, respectively, at 100% (v/v). Homology models of CYP51 exhibited structural reliability based on Ramachandran and validation metrics. Molecular docking identified cis-γ-bisabolene with the lowest binding energies (-7.6 and -7.9 kcal/mol) against haem-free CYP51 models of C. parapsilosis and C. tropicalis, respectively, through hydrophobic interactions. ADMET predictions indicated favorable oral absorption, Lipinski compliance, minimal CYP450 inhibition risk, and no hepatotoxicity or mutagenicity. MD simulations confirmed stable complexes using RMSD, RMSF, Rg, and SASA profiles. MM-PBSA showed favorable binding energies of -6.02 and -8.05 kJ/mol compared to fluconazole (0.98 and 0.66 kJ/mol). DFT showed comparable HOMO-LUMO gaps (6.216 and 6.176 eV) and global hardness (3.108 and 3.088 eV). Overall, HSEO shows promising antifungal potential, with cis-γ-bisabolene as a lead candidate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.